Rhenman & Partners Asset Management AB Buys 125,000 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR

Rhenman & Partners Asset Management AB increased its stake in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 442.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 153,278 shares of the company’s stock after acquiring an additional 125,000 shares during the period. Rhenman & Partners Asset Management AB owned about 0.30% of Immunocore worth $5,320,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of IMCR. Millennium Management LLC lifted its stake in shares of Immunocore by 334.3% in the 3rd quarter. Millennium Management LLC now owns 1,265,965 shares of the company’s stock valued at $45,993,000 after acquiring an additional 974,463 shares during the last quarter. Bellevue Group AG lifted its stake in shares of Immunocore by 14.5% in the 3rd quarter. Bellevue Group AG now owns 2,796,803 shares of the company’s stock valued at $101,608,000 after acquiring an additional 354,973 shares during the last quarter. Fiera Capital Corp lifted its stake in shares of Immunocore by 31.4% in the 4th quarter. Fiera Capital Corp now owns 1,044,831 shares of the company’s stock valued at $36,266,000 after acquiring an additional 249,674 shares during the last quarter. Primecap Management Co. CA lifted its stake in shares of Immunocore by 5.5% in the 4th quarter. Primecap Management Co. CA now owns 3,961,880 shares of the company’s stock valued at $137,517,000 after acquiring an additional 207,320 shares during the last quarter. Finally, Armistice Capital LLC lifted its stake in shares of Immunocore by 21.5% in the 3rd quarter. Armistice Capital LLC now owns 824,000 shares of the company’s stock valued at $29,936,000 after acquiring an additional 146,000 shares during the last quarter. Institutional investors own 84.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on IMCR. Needham & Company LLC boosted their target price on Immunocore from $71.00 to $75.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunocore in a research note on Tuesday, April 21st. Wall Street Zen raised Immunocore from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. HC Wainwright reissued a “buy” rating and issued a $100.00 target price on shares of Immunocore in a research note on Monday, April 20th. Finally, Zacks Research raised Immunocore from a “strong sell” rating to a “strong-buy” rating in a research note on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Immunocore has a consensus rating of “Moderate Buy” and a consensus target price of $56.71.

Immunocore Trading Up 1.2%

IMCR opened at $28.96 on Friday. The business has a 50 day simple moving average of $29.61 and a two-hundred day simple moving average of $32.33. The firm has a market capitalization of $1.47 billion, a price-to-earnings ratio of -52.65 and a beta of 0.74. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.18 and a quick ratio of 4.15. Immunocore Holdings PLC Sponsored ADR has a one year low of $27.56 and a one year high of $40.71.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.51. The business had revenue of $106.68 million during the quarter, compared to analyst estimates of $145.20 million. Immunocore had a negative return on equity of 7.07% and a negative net margin of 6.68%.Immunocore’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.10 EPS. Analysts predict that Immunocore Holdings PLC Sponsored ADR will post 0.06 EPS for the current year.

Immunocore Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.